|Description||TAK-063 is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. TAK-063 is currently being evaluated in clinical trials for the treatment of schizophrenia. Phosphodiesterase 10A (PDE10A) is a cAMP/cGMP phosphodiesterase highly expressed in medium spiny neurons (MSNs) in the striatum. TAK-063 represents a promising drug for the treatment of schizophrenia with potential for superior safety and tolerability profiles.|
|Synonyms||TAK063, TAK 063, TAK-063, Balipodect|
PF-2545920 a highly selective and potent PDE10A inhibitor. It was active with an ED50 of 1 mg/kg.
Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis,...
Cilostazol is a potent cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitor with IC50 of 0.2 μM and inhibitor of adenosine uptake.
Amrinone is a selective cAMP phosphodiesterase (PDE-3) inhibitor with positive inotropic and vasodilatory activity. It is a simple, non-glycoside cardiotonic ag...
PF 04449613 is a potent PDE9 inhibitor (IC50 = 22 nM), and also shows a high affinity for cGMP (Km ~170 nM). Some studies suggest that elevating the level of cG...
Sch59498 is a potent inhibitor of phosphodiesterase 1c (Pde1c) with antihypertensive and antiplatelet effect.
Piclamilast is a potent and selective phosphodiesterase-4 (PDE4) inhibitor (IC50 = 1 nM at PDE4 from human neutrophils) with >19,000-fold selectivity over other...
AWD 12-281 is a strong selective phosphodiesterase 4 (PDE4) inhibitor which has potent effects in models of lung inflammation using inhalative administration.